Due to health issues, this site is no longer maintained and will be shut down shortly. |
Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:ALCLS.
$1.99 -0.05 (-2.45%)
As of 03/27/2023 11:52:27 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.